Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2017

  • ID: 4296606
  • Report
  • 119 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Aerophase Inc
  • Globe Medical Tech Inc
  • Min USA LLC
  • Mylan NV
  • Propeller Health
  • Vectura Group Plc
  • MORE
Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2017

Summary

The author's Medical Devices sector report, “Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Metered Dose Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Metered Dose Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Metered Dose Inhaler Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Metered Dose Inhaler Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment/industry

Reasons to buy

The report enables you to:
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Metered Dose Inhaler Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aerophase Inc
  • Globe Medical Tech Inc
  • Min USA LLC
  • Mylan NV
  • Propeller Health
  • Vectura Group Plc
  • MORE
1 Table of Contents
2 Introduction
2.1 Metered Dose Inhaler Devices Overview
3 Products under Development
3.1 Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
3.2 Metered Dose Inhaler Devices - Pipeline Products by Territory
3.3 Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path
3.4 Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date
3.5 Metered Dose Inhaler Devices - Ongoing Clinical Trials
4 Metered Dose Inhaler Devices - Pipeline Products under Development by Companies
4.1 Metered Dose Inhaler Devices Companies - Pipeline Products by Stage of Development
4.2 Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
5 Metered Dose Inhaler Devices Companies and Product Overview
5.1 Aerophase Inc Company Overview
5.1.1 Aerophase Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Circassia Pharmaceuticals Plc Company Overview
5.2.1 Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
5.3 Globe Medical Tech Inc Company Overview
5.3.1 Globe Medical Tech Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 Lab Automate Technologies Inc Company Overview
5.4.1 Lab Automate Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.5 Medicom Innovation Partner a/s Company Overview
5.5.1 Medicom Innovation Partner a/s Pipeline Products & Ongoing Clinical Trials Overview
5.6 Min USA LLC Company Overview
5.6.1 Min USA LLC Pipeline Products & Ongoing Clinical Trials Overview
5.7 Mylan NV Company Overview
5.7.1 Mylan NV Pipeline Products & Ongoing Clinical Trials Overview
5.8 Propeller Health Company Overview
5.8.1 Propeller Health Pipeline Products & Ongoing Clinical Trials Overview
5.9 Rensselaer Polytechnic Institute Company Overview
5.9.1 Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview
5.10 Vectura Group Plc Company Overview
5.10.1 Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
5.11 Verona Pharma Plc Company Overview
5.11.1 Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
6 Metered Dose Inhaler Devices- Recent Developments
6.1 May 17, 2017: Teva Showcases Asthma Research at the 2017 American Thoracic Society International Conference
6.2 May 10, 2017: Mylan Reports First Quarter 2017 Results
6.3 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy
6.4 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results
6.5 May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors
6.6 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
6.7 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
6.8 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency
6.9 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal
6.10 Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer
6.11 Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016
6.12 Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016
6.13 Mar 06, 2017: Vectura Group: Board Change
6.14 Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance
6.15 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
6.16 Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products
6.17 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
6.18 Jan 26, 2017: Symbicort granted paediatric exclusivity in the US
6.19 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
6.20 Jan 26, 2017: Achievement of sales milestone for COPD products
6.21 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
6.22 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration
6.23 Jan 11, 2017: Vectura Group: Pre-close update
6.24 Dec 21, 2016: Symbicort Maintenance And Reliever Therapy (SMART) now available for adolescents in the UK offering patient-adjusted asthma treatment
6.25 Dec 14, 2016: Consort Medical: Directorate Change
6.26 Dec 06, 2016: Consort Medical Reports Interim Results For The Six Months Ended 31 October 2016
6.27 Dec 01, 2016: Aptar Pharma Nears Completion Of Elastomer Component Capacity In North America
6.28 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
6.29 Nov 25, 2016: Consort Medical: CFO Appointment
6.30 Nov 09, 2016: Mylan Reports Third Quarter 2016 Results
6.31 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
6.32 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results
6.33 Sep 07, 2016: New Scale-Up and Commercial Supply Agreement
6.34 Aug 17, 2016: Consort Medical Announces Directorate Change
6.35 Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8%
6.36 Aug 03, 2016: Boehringer Ingelheim: Growth in all core businesses
6.37 Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
6.38 Jul 08, 2016: Dr John Brown, Non-Executive Director, confirms date to step down
6.39 Jul 04, 2016: Marco Filippini Appointed Vice Coordinator of the Italian Biosimilars Group
6.40 Jun 16, 2016: Consort Medical Announces Final results For The Year Ended 30 April 2016
6.41 Jun 10, 2016: Vectura Group announces Directorate Changes
6.42 Jun 10, 2016: Simone Menne - new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance
6.43 Jun 08, 2016: Merck Expands its Investment Fund Merck Ventures
6.44 May 26, 2016: Vectura Group - Preliminary Results for twelve months ending 31 March 2016
6.45 May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
6.46 May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors
7 Appendix
7.1 Methodology

List of Tables
Table 1: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
Table 2: Metered Dose Inhaler Devices - Pipeline Products by Territory
Table 3: Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path
Table 4: Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date
Table 5: Metered Dose Inhaler Devices - Ongoing Clinical Trials
Table 6: Metered Dose Inhaler Devices Companies - Pipeline Products by Stage of Development
Table 7: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
Table 8: Aerophase Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Metered Dose Inhaler - Product Status
Table 10: Metered Dose Inhaler - Product Description
Table 11: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Fliveo - Product Status
Table 13: Fliveo - Product Description
Table 14: Fluticasone propionate/Salmeterol xinafoate pMDI - Product Status
Table 15: Fluticasone propionate/Salmeterol xinafoate pMDI - Product Description
Table 16: Circassia Pharmaceuticals Plc - Ongoing Clinical Trials Overview
Table 17: Fluticasone propionate/Salmeterol xinafoate pMDI - A Phase III Registration Study of Seretide Substitute (PSX2005)
Table 18: Fluticasone propionate/Salmeterol xinafoate pMDI - An Exploratory, Single-center, Single-dose, Open-label, Randomized, Three-way Crossover Study to Investigate the Pharmacokinetics of Three Orally Inhaled Formulations Containing Fluticasone Propionate and Salmeterol (as Xinafoate) 50/25 mcg Per Actuation Administered From a Pressurized Metered Dose Inhaler, in at Least 24 Healthy Male and Female Subjects
Table 19: Globe Medical Tech Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 20: Inhaler - Product Status
Table 21: Inhaler - Product Description
Table 22: Lab Automate Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 23: Ultrasonic Metered Dose Inhaler - Product Status
Table 24: Ultrasonic Metered Dose Inhaler - Product Description
Table 25: Medicom Innovation Partner a/s Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Asmair - Product Status
Table 27: Asmair - Product Description
Table 28: Min USA LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Envi - Product Status
Table 30: Envi - Product Description
Table 31: Mylan NV Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Metered Dose Inhaler - Product Status
Table 33: Metered Dose Inhaler - Product Description
Table 34: Propeller Health Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Connected Metered Dose Inhaler - Product Status
Table 36: Connected Metered Dose Inhaler - Product Description
Table 37: Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview
Table 38: Bloom Inhaler - Product Status
Table 39: Bloom Inhaler - Product Description
Table 40: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Flutiform HFA-MDI - Product Status
Table 42: Flutiform HFA-MDI - Product Description
Table 43: Flutiform K-Haler - Product Status
Table 44: Flutiform K-Haler - Product Description
Table 45: Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 46: RPL554 - Metered Dose Inhaler - Product Status
Table 47: RPL554 - Metered Dose Inhaler - Product Description
Table 48: Glossary

List of Figures
Figure 1: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
Figure 2: Metered Dose Inhaler Devices - Pipeline Products by Territory
Figure 3: Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path
Figure 4: Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date
Figure 5: Metered Dose Inhaler Devices - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aerophase Inc
  • Circassia Pharmaceuticals Plc
  • Globe Medical Tech Inc
  • Lab Automate Technologies Inc
  • Medicom Innovation Partner a/s
  • Min USA LLC
  • Mylan NV
  • Propeller Health
  • Rensselaer Polytechnic Institute
  • Vectura Group Plc
  • Verona Pharma Plc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll